Relative Bioavailability of BI 207127 Trial Formulation II Prototypes Versus BI 207127 Trial Formulation I in Healthy Volunteers

NCT02182414 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

42

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy

Interventions

DRUG: BI 207127 NA (TF-I)
DRUG: BI 207127 NA (TF-II)
DRUG: BI 207127 NA delayed release
DRUG: BI 207127 NA extended release (10% HPMC)
DRUG: BI 207127 NA extended release (15% PEO)
DRUG: BI 207127 NA extended release (20% HPMC)

Sponsor

Boehringer Ingelheim